| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | 36.993 | 67.389 | 83.273 | 114.778 |
| Total Income - EUR | - | - | - | - | - | - | 36.993 | 67.389 | 83.563 | 114.828 |
| Total Expenses - EUR | - | - | - | - | - | - | 626 | 2.629 | 33.440 | 32.040 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | 36.367 | 64.760 | 50.123 | 82.788 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | 35.280 | 63.474 | 49.307 | 79.414 |
| Employees | - | - | - | - | - | - | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Otorinodan S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | 8 | 993 | 37.806 | 25.302 |
| Current Assets | - | - | - | - | - | - | 35.803 | 63.224 | 45.787 | 81.645 |
| Inventories | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | - | - | 19.726 | 44.476 | 35.721 | 57.768 |
| Cash | - | - | - | - | - | - | 16.077 | 18.748 | 10.066 | 23.878 |
| Shareholders Funds | - | - | - | - | - | - | 35.320 | 63.545 | 49.356 | 79.462 |
| Social Capital | - | - | - | - | - | - | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | - | 491 | 672 | 34.238 | 27.486 |
| Income in Advance | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Otorinodan S.r.l.